Patient-specific tumor neoantigen peptides presented on MHC class I (Neoantigen-MHC I complex)

Patient-specific tumor neoantigen peptides presented on MHC class I represent a class of highly specific therapeutic targets derived from non-synonymous somatic mutations unique to an individual's tumor. These neoantigens are processed intracellularly and presented on the cell surface by Major Histocompatibility Complex (MHC) class I molecules, where they can be recognized by the T-cell receptors (TCRs) of CD8+ cytotoxic T cells. Because these antigens are not expressed in normal tissues, they are ideal targets for personalized immunotherapy, minimizing the risk of central tolerance and autoimmune cross-reactivity. Current therapeutic strategies include personalized mRNA or DNA vaccines and adoptive T-cell therapies designed to amplify the immune system's ability to detect and destroy cells harboring these specific mutations. The identification of these targets typically requires high-throughput sequencing and sophisticated bioinformatic algorithms to predict which mutations will result in peptides with high binding affinity for the patient's specific HLA alleles.

Other names

Tumor-specific neoantigens (TSAs)NeoepitopesMHC-I-restricted neoantigensPersonalized tumor antigensSomatic mutation-derived peptides

Drugs targeting these complexes, such as personalized vaccines, work by delivering the genetic sequence or synthetic version of the neoantigen to the patient. This primes and expands the population of endogenous CD8+ cytotoxic T cells that specifically recognize the neoantigen-MHC I complex on the surface of tumor cells, leading to targeted lysis of the cancer cells while sparing healthy tissue.